$25 Billion Global CFTR Modulator Market Opportunity, Dosage, Price and Clinical Trial Overview 2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The report “Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2028” has been added to from ResearchAndMarkets.com offer.
The report provides a comprehensive overview of the clinical and non-clinical factors driving the global CFTR Modulator market and its impact on the global pharmaceutical market landscape.
The approval of the first CF transmembrane conductance regulator (CFTR) modulator has changed the face of cystic fibrosis in the era of precision medicine. Cystic fibrosis is a rare, life-shortening genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene – or CFTR. These modulators are designed to correct the faulty protein made by the CFTR gene. This class of drugs has grown significantly since 2012, with up to four agents available on the global market. Kalydeco was the first approved CFTR modulator drug that showed a robust response in the market by significantly increasing median survival rates in patients. The complexity of the disease has prompted the development of several combination therapies that can better tackle the complex nature of the disease. To overcome this, Orkambi, Symdeko and Trikafta have been approved and belong to the class of CFTR combinatorial drugs. Currently, the market is dominated by combination drugs due to their increased efficacy in disease management and their ability to overcome the limitations of monotherapy.
The encouraging response of CFTR modulators in the market has led to new research and development activities in this area. Several promising compounds are currently being evaluated and may prove to be alternatives to VX-770 for overcoming trigger mutations. Vertex Pharmaceutical is conducting a clinical trial of VX-561 (also known as deutivacaftor), an analog of VX-770 in which one of the tert-butyl groups has been replaced with a per-deuterated group. Preclinical data demonstrated that the drug has similar activity to VX-770; however, it has increased stability suggesting that it could only be prescribed once a day, unlike VX-770, which must be administered every 12 hours. The company is also developing another corrector, VX-121, which has reached clinical phase 3. It is being evaluated in combination with VX-661, VX-770 and/or VX-56.
Although CFTR modulators have been shown to dominate the CF treatment market, several challenges still need to be overcome. Currently available CFTR modulating drugs target the underlying cause of cystic fibrosis. However, some patients with rare CFTR mutations are still not eligible to receive currently marketed treatments. Therefore, developers still have the option to study CFTR modulators for less common mutations. Additionally, resistance to these drugs is another challenge that needs to be overcome.
The global market for CFTR modulators is expected to exceed US$25 billion by 2028. The growing prevalence and increasing funding from several non-profit organizations including Cystic Fibrosis Foundation, Cystic Fibrosis Worldwide, South African Cystic Fibrosis Trust and the South African Cystic Fibrosis Association, to stimulate market growth but also encourage research and development activities in cystic fibrosis. These organizations are investing huge sums to find various CFTR modulators for cystic fibrosis and to support the research and development activities of leading players. Additionally, the strong clinical pipeline of drugs that will be approved over the forecast period will also drive the market growth.
The report provides comprehensive details of existing pure-play companies and new players entering the market with key drugs in research and development. Additionally, the report provides an overview of the major challenges that will hinder the market growth during the forecast period. Additionally, the report provides information on globally approved CFTR modulators along with their patent, price, dosage and sales analysis till Q1 2022.
Main highlights of the report:
Global CFTR Modulator Market Opportunity: >USD 25 Billion
Global CFTR Modulator Market Overview: Current, Regional and Future Outlook 2028
Overview of annual, quarterly and regional sales of CFTR modulators
Availability of CFTR Modulators by Dosage, Patent and Price Analysis
Clinical insight on over 30 CFTR modulators in trials
Overview of clinical trials on CFTR modulators by country, company and phase: > 30 drugs
Main topics covered:
1. Introduction to CFTR Modulators
1.2 Evolution of CFTR modulators
2. Global Mechanism of Action of CFTR Modulators
3. US CFTR Modulator Market Overview
4. ROW CFTR Modulator Market Overview
5. Ivacaftor (Kalydeco) – Clinical and Business Overview
6.2 Patents and assignees
6.3 Pricing and Dosage Overview
6.4 Sales Analysis
6. Ivacaftor/Lumacaftor (Orkambi) – Clinical and Commercial Overview
7.2 Patents and assignees
7.3 Price and Dosage Overview
7.4 Sales Analysis
7. Tezacaftor/Ivacaftor (Symdeko) – Clinical and Commercial Overview
8.2 Patent and assignees
8.3 Price and Dosage Overview
8. Elexacaftor/Ivacaftor/Tezacaftor (Trikafta) – Clinical and Market Overview
9.2 Patent and assignees
9.3 Price and Dosage Overview
9.4 Global Sales
9. Global Vaccine Pipeline Overview for CFTR Modulators
10.1 By country
10.2 By Company
10.3 By Patient Segment
10.4 By stage
10. Overview of Global Clinical Trials of CFTR Modulators
11.3 Stage I
11.4 Phase I/II
11.5 Phase II
11.6 Stage III
11. Marketed CFTR Modulators Clinical Overviews
12. CFTR Modulator Drugs Market Dynamics
13.1 Favorable parameters
13.2 Market Constraints
13. CFTR Modulator Market Future Prospect
14. Competitive landscape
Realta Life Sciences
Southern Research Institute
4D Molecular Therapeutics
For more information on this report visit https://www.researchandmarkets.com/r/ddmvxo
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.